Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLAG + Bu/Cy conditioning for allogeneic cord blood transplant in pediatric high-risk acute leukemia
ChiCTR2200062540Phase 4Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2022
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine, cytarabine, granulocyte colony-stimulating factor, busulfan and cyclophosphamide in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and Acute Leukaemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Overall survival and Leukemia-free survival. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
cladribinecytarabinegranulocyte colony-stimulating factorbusulfancyclophosphamide
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)Acute Leukaemia
Beyond the preview
Go deeper on ChiCTR2200062540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062540.